Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma
- 249 Downloads
Complete macroscopic resection surgery, pleurectomy and decortication (PD) improve survival in selected patients with malignant pleural mesothelioma (MPM). Yet its value has been questioned because of concern that this extensive surgical procedure may disrupt health-related quality of life (HRQoL).
HRQoL was studied in patients undergoing PD surgery for MPM using EORTC QLQ-C30 instrument at baseline (prior to surgery), 1, 4–5, 7–8, and 10–11 months following surgery. Global health and variables in function and symptom domains were investigated. Sub-groups analyses were performed for ECOG performance status (PS), histological sub-types and pathological tumor volume (pTV). Within-patient comparisons to baseline scores were made using Wilcoxon signed-rank test. Trends over time were evaluated using Cuzick’s nonparametric test.
There were 114 patients with median age of 70 years (range: 50–88) and PS 0: 35 (30.7%), epithelioid histology: 61 (53.5%) and volume <600 ml: 58 (50.9%). Patients with good PS (PS 0), epithelioid histology and small pTV had greater level of functioning and were less symptomatic at baseline. Overall global health worsened at the first postoperative month (p = 0.0005) with subsequent improvement. Non-epithelioid histology and patients with large pTV demonstrated greater improvement in global health, function and symptoms domains following a PD.
At baseline, the overall health-related quality of life, function and symptom domains were adversely affected in non-epithelioid histology and patients with large pTV. However, greatest improvement in global health, symptom and function domains were observed first month after PD and during the follow-up in these sub-groups.
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
- 1.Betta PG, Magnani C, Bensi T et al (2012) Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma. Arch Pathol Lab Med 136(253):261Google Scholar
- 2.Elliot W, Kammerstern M, Churg J (1983) Tumors and pseudotumors of the serous membranes. In: Atlas of tumor pathology. Second series, fascicle 20. Armed Forces Institute of Pathology, Washington, DCGoogle Scholar
- 5.Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16(145):52Google Scholar
- 6.Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, Rusch VW (2014) Supplementary prognostic variables for pleural mesothelioma a report from the IASLC Staging Committee. J Thorac Oncol 9(6):856.64CrossRefPubMedGoogle Scholar
- 11.Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual, 3rd edn. on behalf of the EORTC Quality of Life Group. Brussels: EORTC. ISBN: 2-9300 64-22-6Google Scholar
- 12.Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J et al (2011) Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 6(8):1304.12CrossRefPubMedGoogle Scholar
- 14.Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16(145):52Google Scholar
- 17.Rusch V, Baldini EH, Bueno R et al (2013) participants in 2012 International Mesothelioma Interest Group Congress. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, MA. J Thorac Cardiovasc Surg 145:909–910CrossRefPubMedGoogle Scholar